EXACT Therapeutics’ clinical trials
The ENACT study
EXACT is preparing to start a Phase 2 study where the safety and efficacy of ACT will be investigated in combination with standard of care chemotherapy as 1st line treatment in patients with borderline resectable or unresectable locally advanced pancreatic cancer – the ENACT study.
The ACTIVATE study
Safety and anticancer activity of ACT® is currently being evaluated in a Phase I, multi-centre, clinical trial (NCT04021277) in patients with liver metastases secondary to colorectal cancer – the ACTIVATE study.
ACTIVATE is led by Professor Udai Banerji from the Institute of Cancer Research, The Royal Marsden Hospital, UK. Other principal investigators are Professor Ruth Plummer (Freeman Hospital, Newcastle), Dr. Bristi Basu (Cancer Research UK; University of Cambridge), and Professor Geir Olav Hjortland (Oslo University Hospital).
ACTIVATE is currently recruiting patients for the dose expansion part.
In the study, we use an innovative approach to assess within-patient effect of the combination of ACT with chemotherapy against chemotherapy alone by insonating one cancer lesion in the liver and comparing change in tumour size and volume with tumour lesions that have not been insonated.
Results of the dose escalation part showed that the ACT treatment is safe and had greater anticancer activity than chemotherapy without AC
For patients interested in enrolling in the study, please reach out to Dr. Udai Banerji at the Institute of Cancer Research
8 patients enrolled, 6 evaluable for dose limit toxicities
No adverse events considered by the investigator related to PS 101 or the ultrasound
